DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non–muscle-invasive Bladder Cancer

Puntos clave

• This research examines the long-term effects of chemoresection with mitomycin C for treating recurrent non-muscle-invasive bladder cancer (NMIBC).
• Conducted a five-year follow-up of a randomized controlled trial
• Evaluated oncological outcomes in patients receiving chemoresection with mitomycin C
• Compared results to traditional surgical interventions
• Chemoresection significantly reduced the need for invasive surgical procedures
• Long-term oncological outcomes were maintained
• Integration of this treatment is supported for selected patients